EMA Review of Daunorubicin and Cytarabine Encapsulated in Liposomes (Vyxeos, CPX‐351) for the Treatment of Adults with Newly Diagnosed, Therapy‐Related Acute Myeloid Leukemia or Acute Myeloid Leukemia with Myelodysplasia‐Related Changes

On June 28, 2018, the Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vyxeos, intended for the treatment of acute myeloid leukemia (AML). Vyxeos was designated as an orphan medicinal product o...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncologist
Главные авторы: Tzogani, Kyriaki, Penttilä, Karri, Lapveteläinen, Tuomo, Hemmings, Robert, Koenig, Janet, Freire, João, Márcia, Silva, Cole, Susan, Coppola, Paola, Flores, Beatriz, Barbachano, Yolanda, Roige, Silvia Domingo, Pignatti, Francesco
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley & Sons, Inc. 2020
Предметы:
Regulatory Issues: EMA
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7485353/
https://ncbi.nlm.nih.gov/pubmed/32282100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0785
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы